Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cefadroxil for Oral Suspension USP 250mg/5mL and 500mg/5mL.
Cefadroxil for Oral Suspension USP, 250mg/5mL and 500mg/5mL is the generic equivalents of Warner Chilcott Company, Inc’s Duricef for Oral Suspension 250mg/5mL and 500mg/5mL. Cefadroxil is a cephalosporin antibiotic indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms such as urinary tract infections caused by E.coli, P.mirabilis, and Klebsiella species; skin and skin structure infections caused by staphylococci and/or streptococci; Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes.
The product has been approved out of Unit VI Cephalosporin formulations manufacturing facility in Hyderabad, India. The company now has a total of 187 ANDA approvals (160 Final approvals including 4 from Aurolife Pharma LLC and 27 Tentative approvals) from USFDA.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: